Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-28T23:50:22.613Z Has data issue: false hasContentIssue false
  • English
  • Français

Gene Therapy: A New Challenge for Infection Control

Published online by Cambridge University Press:  02 January 2015

David J. Weber  and
William A. Rutala
David J. Weber*
Affiliation:
Division of Infectious Diseases, University of North Carolina School of Medicine, and the Department of Hospital Epidemiology, University of North Carolina Health Care System, Chapel Hill, North Carolina
William A. Rutala
Affiliation:
Division of Infectious Diseases, University of North Carolina School of Medicine, and the Department of Hospital Epidemiology, University of North Carolina Health Care System, Chapel Hill, North Carolina
*
547 Burnett-Womack, CB #7030, Division of Infectious Diseases, UNC at Chapel Hill, Chapel Hill, NC 27599-7030
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Infection Control & Hospital Epidemiology , Volume 20 , Issue 8 , August 1999 , pp. 530 - 532
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1999

References

1.Fishman, JA. Xenosis and xenotransplantation: addressing the infectious risks posed by an emerging technology. Kidney lnt Suppl 1997;58:S41–S45.Google Scholar
2.Michaels, MG. Infectious concerns of cross-species transplantation: xenozoonoses. World J Surg 1997;21:968–974.Google Scholar
3.Patience, C, Takeuchi, Y, Weiss, RA. Zoonosis in xenotransplantation. Curr Opin Immunol 1998;10:539–542.Google Scholar
4.Fishman, JA. The risk of infection in xenotransplantation. Ann NY Acad Sci 1998;862:45–51.Google Scholar
5.Borie, DC, Cramer, DV, Phan-Thanh, L, Vaillant, JC, Bequet, JL, Makowka, L, et al. Microbiological hazards related to xenotransplantation of porcine organs into man. Infect Control Hosp Epidemiol 1998;19:355–365.Google ScholarPubMed
6.Allan, JS. The risk of using baboons as transplant donors. Ann NY Acad Sci 1998;862:87–99.Google Scholar
7.Simon, JD. Biological terrorism. JAMA 1997;278:428–430.Google Scholar
8.Cams, WS. Biological warfare threats in perspective. Crit Rev Micriobiol 1998;24:149–155.Google Scholar
9.Christopher, GW, Cieslak, TJ, Pavlin, JAEitzen, EM. Biological warfare: a historical perspective. JAMA 1997;278:412–417.Google Scholar
10.Franz, DR, Jahrling, PB, Friedlander, AM, McClain, DJ, Hoover, DL, Bryne, WR, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399–411.Google Scholar
11.Atlas, RM. The medical threat of biological weapons. Crit Rev Microbiol 1998;24:157–168.Google Scholar
12.Public Health Service. Draft public health service guideline on infectious disease issues in xenotransplantation. Federal Register September 23,1996;61:49920–49932.Google Scholar
13.Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management—United States, 1998. MMWR 1999;48:69–74.Google Scholar
14.English, JF, Cundiff, MY, Malone, JD, Pfeiffer, JABell, M, Steele, L, et al. Bioterrorism readiness plan: a template for healthcare facilities. http://www.apic.org/html/educ/readinow.html.Google Scholar
15.Weber, DJ, Hoffmann, KK, Rutala, WA. Infection control in gene therapy. In: Mayhall, GG, ed. Hospital Epidemiology and Infection Control. Baltimore, MD: Williams & Wilkins; 1996:794–797.Google Scholar
16.Blaese, RM, Culver, KW, Miller, AD, Carter, CS, Fleisher, T, Clerici, M, et al. T lymphocyte-directed gene therapy for ADA sup minus SCID: initial trial results after 4 years. Science 1995;270:465–480.Google Scholar
17. The Journal of Gene Medicine Website. The Clinical Trials Website. http://www.wiley.co.uk/genmed.Google Scholar
18.Russell, SJ. Science, medicine, and the future: gene therapy. BMJ 1997;315:1289–1292.Google Scholar
19.Feuerbach, FJ, Crystal, RG. Progress in human gene therapy. Kidney lnt 1996;49:1791–1794.Google Scholar
20.Friedmann, T. Overcoming the obstacles to gene therapy. Sci Am 1997;276:96–101.Google Scholar
21.Felgner, PL. Nonviral strategies for gene therapy. Sci Am 1997;276:102–106.CrossRefGoogle ScholarPubMed
22.Wivel, NA, Wilson, JM. Methods of gene delivery. Hematol Oncol Clin North Am 1998;12:483–501.CrossRefGoogle ScholarPubMed
23.Evans, ME, Lesnaw, JA. Infection control in gene therapy. Infect Control Hosp Epidemiol 1999;20:568–576.Google Scholar
24.US Department of Health and Human Services. Biosafety in Microbiology and Biomedical Laboratories. 3rd ed. Washington, DC: US Government Printing Office; 1993.Google Scholar
25.Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens. Federal Register December 6, 1991;56:64175–64182.Google Scholar
26.National Institutes for Health. Guidelines for research involving recombinant DNA molecules (NIH guidelines), May 1998. www.nih. gov/od/orda/toc.htm.Google Scholar
27.Center for Biologies Evaluation and Research, Food and Drug Administration. Guidance for human somatic cell therapy and gene therapy, March 1998. Human Gene Therapy 1998;9:1513–1524 (also www.fda.gov/cber/guidelines.htm).Google Scholar
28.Duque, MDPM, Sanchez-Preito, R, Lieonart, M, Cajal, SRY. Perspectives in gene therapy. Histol Histopathol 1998;13:231–242.Google Scholar
29.Kmiec, EB. Gene therapy. American Scientist 1999;87:240–247.Google Scholar
30.Weber, DJ, Durand, M, Rutala, WA. Nosocomial ocular infections. In: Mayhall, GG, ed. Hospital Epidemiology and Infection Control. 2nd ed. Baltimore, MD: Williams & Wilkins. In press.Google Scholar
31.Weber, DJ, Barbee, SL, Sobsey, MD, Rutala, WA. The effect of blood on the antiviral activity of sodium hypochlorite, a phenolic, and a quaternary ammonium compound. Infect Control Hosp Epidemiol 1999. In press.Google Scholar